What is Accro BioScience?
Accro BioScience, established in late 2017, is a biotechnology firm concentrating its research on the intricate molecular mechanisms of regulated cell death, including necroptosis, pyroptosis, and ferroptosis. These processes are critically implicated in the pathogenesis of numerous major human diseases, positioning Accro BioScience at the forefront of developing novel therapeutic strategies.
How much funding has Accro BioScience raised?
Accro BioScience has raised a total of $50M across 1 funding round:
Series B
$50M
Series B (2022): $50M with participation from Shenzhen Capital Group, Suzhou Oriza Holdings, South China Venture Capital, and Hongtai Aplus
Key Investors in Accro BioScience
Shenzhen Capital Group
Shenzhen Capital Group is a prominent investment firm that likely focuses on technology and innovation sectors, providing capital to companies with high growth potential.
South China Venture Capital
South China Venture Capital, established in 2008, manages multiple RMB and USD venture capital funds focusing on early to growth-stage investments in the fields of biomedicine, semiconductors, and artificial intelligence. The company aims to empower technology with capital and believes in creating value through innovation and collaboration with entrepreneurs.
Suzhou Oriza Holdings
Undisclosed investor participating in the funding round.
What's next for Accro BioScience?
The recent major enterprise-level funding and strategic investment signal a pivotal growth phase for Accro BioScience. This capital infusion is expected to accelerate research and development efforts, potentially enabling the company to advance its pipeline candidates through preclinical and clinical trials. The focus on fundamental cell death pathways suggests a long-term vision for addressing complex, unmet medical needs, positioning the company for significant future milestones and potential market impact.
See full Accro BioScience company page
